Evidence map›Paper›PMID 40097491›Full record

ArticleScientific reports2025

Protein kinase C epsilon activation improves early survival in an acute porcine model of controlled hemorrhage.

Maya Simchoni, Linn Wagnert-Avraham, Estela Derazne, Dean Nachman, Yuval Gershon, Eliraz Cohen Levi, Adi Horesh, Yaron Cohen, Maya Nitecki, Yuval Glick and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Maya SimchoniDepartment of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel.
Linn Wagnert-AvrahamThe Institute for Research in Military Medicine (IRMM), Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Estela DerazneFaculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Dean NachmanThe Institute for Research in Military Medicine (IRMM), Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Yuval GershonDepartment of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel.
Eliraz Cohen LeviDepartment of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel.
Adi HoreshDepartment of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel.
Yaron CohenDepartment of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel.
Maya NiteckiDepartment of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel.
Yuval GlickDepartment of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel.
Arik EisenkraftThe Institute for Research in Military Medicine (IRMM), Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Nir SuissaDepartment of Neurology, Hadassah Medical Center, Jerusalem, Israel.
Gilad TwigDepartment of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
S David GertzThe Institute for Research in Military Medicine (IRMM), Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Ann SaadaDepartment of Genetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Ariel FurerDepartment of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel. furera@gmail.com.

Funding

The Israel Defense Forces Medical Corps and Directorate of Defense Research and Development, Israeli Ministry of Defense 4440701101
6 · The paper itself

Abstract

Hemorrhage is the primary cause of preventable death in both military and civilian trauma cases, and the effective therapeutic options are limited. Activation of Protein Kinase C epsilon (PKC-ε) was shown to have a protective role in ischemia-reperfusion injury models. Thus, we evaluated the effects of a PKC-ε activator peptide in a swine model of controlled hemorrhagic shock. Controlled hemorrhage was induced in 25 Sus Domesticus female pigs by blood withdrawal. Fifteen animals were treated with PKC-ε activator peptide (3 mg/kg IM) five minutes following the initiation of hemorrhage, and 8 animals were bled without receiving the peptide. Two additional animals were treated with the peptide without having been bled for safety validation. Hemodynamic and biochemical parameters were monitored for 7 h, and mitochondrial function markers were analyzed and compared between groups. 73.3% of the pigs that received the peptide survived the hemorrhage until the end of the follow-up compared to only 25% of non-treated control animals. Kaplan-Meier survival analysis showed a significant difference between the groups (p = 0.044). This benefit was associated with a more favorable hemodynamic profile, including more stable blood pressure, heart rate and cardiac output, and a better acid-base balance. Mitochondrial analysis identified a significant increase in electron transport chain complex-I activity in the myocardium of treated animals compared with the controls (p = 0.033). In conclusion, Administration of PKC-ε activator is associated with improved survival, hemodynamic stability, and mitochondrial function in a porcine model of controlled hemorrhage.

Indexed as

HemorrhageProtein Kinase C-epsilonShock, HemorrhagicAnimalsDisease Models, AnimalEnzyme ActivationFemaleHemodynamicsSwineProtein Kinase C-epsilonHemorrhagic shockIschemia–reperfusion injuryPKC-εSurvival

Identifiers

PMID40097491
PMCPMC11914495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.